

Special Issue

Emerging and Re-emerging Animal Viral Diseases and Viral Diseases with Zoonotic Potential

Message from the Guest Editors

This Special Issue aims to show novel and high impact results in the field of emerging and re-emerging viral diseases that may affect livestock, poultry and wild animals, and that can also cause disease in humans (zoonoses). The current issue will be opened not just to manuscripts focused on vaccine development and new antigen discovery, but also to studies focused on viruses replication and spread, viruses transmission, pathogenic mechanisms, virus–host interactions, immune response induced against virus infections, immune mechanisms involved in protection or any other state-of- the-art study that might contribute to prevent and control these viral diseases in livestock and the transmission from animal to human. We encourage authors to present original results obtained after carrying out “in vivo” experiments that require the use of small animal models (e.g., murine models), as well as natural or intermediate hosts. We will also consider “in vitro” studies. Only high-quality reviews tackling novel issues in the field will be considered.

Guest Editors

Dr. Giulia Franzoni

Dr. Miriam Pedrera

Dr. Pedro J. Sanchez-Cordon

Deadline for manuscript submissions

closed (30 November 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/152826

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).